CD4/CD8 ratio according to the presence and type of event.

<p>The CD4/CD8 in controls [0.70 (IQR 0.48–0.94)] was significantly higher than in subjects who developed non-AIDS events [0.46 (IQR 0.31–0.68), <i>P</i><0.0001], including non-AIDS defining malignancies (N = 35) [0.44 (IQR 0.25–0.71), <i>P</i> = 0.0001], Hodgkin lymphoma (N = 10) [0.41 (IQR 0.33–0.57), <i>P = </i>0.0039], ischemic heart disease (N = 38) [0.47 (IQR 0.32–0.63), <i>P</i> = 0.0001], stroke (N = 15) (0.46 [IQR 0.28–0.83), <i>P</i> = 0.013), and end-stage kidney disease (N = 9) [0.33 (0.32–0.53), P = 0.028]. The CD4/CD8 ratio was also significantly lower in subjects with non-AIDS associated mortality (N = 29) [0.33 (IQR 0.22–0.46), <i>P</i><0.0001].